MaxCyte, Inc. filings document the regulatory record for a Delaware life sciences tools company with Nasdaq-listed common stock. Its Form 8-K disclosures cover operating results and financial condition, corporate presentations, executive appointments, compensatory arrangements, listing-compliance notices, and cost-structure actions tied to workforce and operating changes.
MaxCyte proxy materials cover annual stockholder meeting matters, including director elections, board-class structure and auditor ratification. Together, the filings describe governance, capital-market status, material events, and formal disclosures related to MaxCyte’s cell-engineering platform business, Strategic Platform License model, and public-company reporting obligations.
For MaxCyte, Inc. (MXCT), Liontrust Investment Partners LLP reported beneficial ownership of 5,081,403 equity shares, or 4.9235% of the class, with sole voting and dispositive power over that amount. Its transaction table lists sales from August 6 through October 30, 2026, and purchases on October 14, including an October 30 sale of 112,919 shares and three October 14 purchases of 138,139, 175,694 and 43,113 shares. Jasmine Purohit signed as Compliance Executive.
MaxCyte, Inc. (MXCT) is the issuer in a Schedule 13D reporting that Liontrust Investment Partners LLP, an investment firm, beneficially owned 5,194,322 shares, or 5.0330% of the class, with sole voting and dispositive power over that amount.
The reported transaction history lists sales dated September 1, September 2, September 3, September 8, September 9, September 10, September 11, September 14, and October 7, 2026. The October 14, 2026 entries list purchases of 138,139, 175,694 and 43,113 shares, each at $1.26072563 per share. A September 1, 2026 sale involved 81,203 shares at $1.23950150 per share.
MaxCyte (MXCT) reported preliminary, unaudited revenue for the third quarter ended September 30, 2026, and raised full-year 2026 revenue guidance for its core business and SPL Program-related revenue. The updated core-business outlook reflects approximately 15% year-over-year growth in the second half of 2026.
MaxCyte said accelerated instrument purchasing from a large customer drove third-quarter results; it had initially expected that purchasing in the fourth quarter. The company also raised SPL Program-related guidance after recognizing a milestone from one partner, its second milestone achieved in 2026. The preliminary results remain subject to quarter-end closing procedures and review of interim financial statements, and actual results may differ. MaxCyte scheduled its third-quarter earnings call for November 10, 2026.
MaxCyte, Inc. reported lower revenue and a smaller loss for the quarter ended June 30, 2026. Q2 revenue was $7.3 million, down from $8.5 million a year earlier, with core revenue falling 21% while SPL milestones and royalties more than doubled. Gross margin declined to 77%.
Operating expenses fell sharply to $15.8 million from $21.2 million, driven by a 2025 workforce reduction and lower stock-based compensation, partly offset by a $1.6 million write-off of abandoned asset-acquisition costs and a $0.6 million asset impairment. Net loss improved to $8.9 million in Q2 and $13.6 million for the first half. The company used $12.8 million in operating cash in the first six months, ending June 30, 2026 with $15.0 million in cash and $126.9 million in short- and long-term investments, no debt, and $158.8 million in stockholders’ equity. MaxCyte began a share repurchase program, buying 1.3 million shares for $1.5 million in the first half and an additional 2.9 million shares for $4.0 million after quarter-end.
MaxCyte, Inc. reported financial results for the quarter ended June 30, 2026 and reiterated its full year 2026 guidance. Second-quarter revenue was $7,271 thousand, down from $8,507 thousand a year earlier, with instruments, consumables and license revenue lower, partially offset by higher assay services and other revenue.
The company recorded a net loss of $8,874 thousand for the quarter, improving from a $12,357 thousand net loss in 2025, and management highlighted a meaningful reduction in net loss in the first half of 2026. Royalty revenue grew to $764 thousand, and the company cited an enterprise-level multi-platform technology license with Genentech as an important recent development. As of June 30, 2026, MaxCyte held $15,042 thousand in cash and cash equivalents and $90,648 thousand in short-term investments.
River Global Investors LLP reports beneficial ownership of 834,100.00 MaxCyte, Inc. shares, representing 0.7786% of the company’s equity, with sole voting and dispositive power over this stake as of July 31, 2026.
This position follows an extraordinary corporate transaction in which the FCA approved the change in control and proposed acquisition of River Global Holdings Limited. After this approval, Liontrust Investment Partners LLP assumed responsibility for the River Global Investors ICVC and ICAV funds, and voting rights attached to approximately 4.3% of MaxCyte shares transferred from River Global Investors to Liontrust. Approximately 0.8% voting rights remain with River Global Investors and will be transferred at a later stage.
BlackRock, Inc. reports its institutional ownership position in MaxCyte, Inc. common stock. As of June 30, 2026, BlackRock beneficially owned 1,402,591 shares of MaxCyte common stock, representing 1.3% of the outstanding class. BlackRock has sole voting power and sole dispositive power over all 1,402,591 shares, with no shared voting or dispositive power.
The filing notes that various underlying clients have the right to receive dividends or sale proceeds from these shares, but no single person has an interest in more than five percent of MaxCyte’s total outstanding common shares. This amendment reflects BlackRock’s status as a holder of 5 percent or less of the class.
Johnston John Joseph reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. director John Joseph Johnston received 30,421 restricted stock units, each representing one share of common stock, as part of his annual non-employee director grant. He also received a stock option for 49,579 shares at $1.13 per share, expiring in 2036. The RSUs vest on June 17, 2027, subject to continued service, bringing his direct common stock holdings to 201,581 shares.
Hemrajani Rekha reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. director Rekha Hemrajani reported equity awards consisting of restricted stock units and stock options. She received 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with a strike price of $1.13 per share, expiring on June 16, 2036. The annual grant for non-employee directors vests on June 17, 2027, subject to her continuous service, bringing her direct common stock holdings to 70,314 shares.
MAXCYTE, INC. director Stanley C. Erck received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one common share, and an option for 49,579 shares at an exercise price of $1.13 per share, expiring on June 16, 2036. The RSUs vest on June 17, 2027, subject to his continued service, and his direct common stock holdings after the grant total 428,749 shares.